Experience with the clinical development of influenza vaccines for potential pandemics
Identifieur interne : 001777 ( Main/Exploration ); précédent : 001776; suivant : 001778Experience with the clinical development of influenza vaccines for potential pandemics
Auteurs : J. Wood [Royaume-Uni] ; K. Nicholson [Royaume-Uni] ; I. Stephenson [Royaume-Uni] ; M. Zambon [Royaume-Uni] ; R. Newman [Royaume-Uni] ; D. Major [Royaume-Uni] ; A. Podda [Italie]Source :
- Medical Microbiology and Immunology [ 0300-8584 ] ; 2002-12-01.
English descriptors
- KwdEn :
Abstract
Abstract.: During normal interpandemic influenza seasons, immune responses to vaccines are quite predictable and meet the licensing criteria of the European Union (EU) Committee for Proprietary Medicinal Products (CPMP). In a pandemic situation, large sections, if not all of the community will be immunologically naïve and therefore new immunisation strategies will be needed. In 1976 and 1977 H1N1 vaccines were prepared and tested clinically. To stimulate 'protective' antibody responses, two doses of vaccine were needed in people below the age of 24 years (no previous experience of H1N1 virus), whereas one conventional dose was adequate in older people. In 1997, the highly pathogenic avian influenza H5N1 virus caused widespread concern when it infected man, with lethal effects. Due to safety concerns it was necessary to adopt new strategies for vaccine development and one such strategy was to produce vaccine from an avirulent H5N3 virus, A/Duck/Singapore-Q/F119-2/97. Clinical trials of a subunit vaccine prepared from A/Duck/Sing/97 virus revealed that even two doses of twice the normal vaccine concentration (i.e. 30 µg haemagglutinin) were poorly immunogenic, whereas an H5N3 vaccine adjuvanted with microfluidised emulsion (MF) 59 stimulated antibody levels that complied with CPMP criteria after two half strength doses (i.e. 7.5 µg haemagglutinin).
Url:
DOI: 10.1007/s00430-002-0146-x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A75
- to stream Istex, to step Curation: 000A75
- to stream Istex, to step Checkpoint: 000624
- to stream Main, to step Merge: 001815
- to stream Main, to step Curation: 001777
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Experience with the clinical development of influenza vaccines for potential pandemics</title><author><name sortKey="Wood, J" sort="Wood, J" uniqKey="Wood J" first="J." last="Wood">J. Wood</name></author><author><name sortKey="Nicholson, K" sort="Nicholson, K" uniqKey="Nicholson K" first="K." last="Nicholson">K. Nicholson</name></author><author><name sortKey="Stephenson, I" sort="Stephenson, I" uniqKey="Stephenson I" first="I." last="Stephenson">I. Stephenson</name></author><author><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name></author><author><name sortKey="Newman, R" sort="Newman, R" uniqKey="Newman R" first="R." last="Newman">R. Newman</name></author><author><name sortKey="Major, D" sort="Major, D" uniqKey="Major D" first="D." last="Major">D. Major</name></author><author><name sortKey="Podda, A" sort="Podda, A" uniqKey="Podda A" first="A." last="Podda">A. Podda</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:531EA83777D63FF171A11EEEF568B5B739EF8C08</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1007/s00430-002-0146-x</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-0SX8TQ0L-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A75</idno><idno type="wicri:Area/Istex/Curation">000A75</idno><idno type="wicri:Area/Istex/Checkpoint">000624</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000624</idno><idno type="wicri:doubleKey">0300-8584:2002:Wood J:experience:with:the</idno><idno type="wicri:Area/Main/Merge">001815</idno><idno type="wicri:Area/Main/Curation">001777</idno><idno type="wicri:Area/Main/Exploration">001777</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Experience with the clinical development of influenza vaccines for potential pandemics</title><author><name sortKey="Wood, J" sort="Wood, J" uniqKey="Wood J" first="J." last="Wood">J. Wood</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG</wicri:regionArea><wicri:noRegion>EN6 3QG</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Nicholson, K" sort="Nicholson, K" uniqKey="Nicholson K" first="K." last="Nicholson">K. Nicholson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, LE1 5WW</wicri:regionArea><wicri:noRegion>LE1 5WW</wicri:noRegion></affiliation></author><author><name sortKey="Stephenson, I" sort="Stephenson, I" uniqKey="Stephenson I" first="I." last="Stephenson">I. Stephenson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, LE1 5WW</wicri:regionArea><wicri:noRegion>LE1 5WW</wicri:noRegion></affiliation></author><author><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Public Health Laboratory Service, 61 Colindale Avenue, London, NW9 5EQ</wicri:regionArea><wicri:noRegion>NW9 5EQ</wicri:noRegion></affiliation></author><author><name sortKey="Newman, R" sort="Newman, R" uniqKey="Newman R" first="R." last="Newman">R. Newman</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG</wicri:regionArea><wicri:noRegion>EN6 3QG</wicri:noRegion></affiliation></author><author><name sortKey="Major, D" sort="Major, D" uniqKey="Major D" first="D." last="Major">D. Major</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG</wicri:regionArea><wicri:noRegion>EN6 3QG</wicri:noRegion></affiliation></author><author><name sortKey="Podda, A" sort="Podda, A" uniqKey="Podda A" first="A." last="Podda">A. Podda</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Chiron SpA, via Fiorentina 1, 53100 Siena</wicri:regionArea><wicri:noRegion>53100 Siena</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Microbiology and Immunology</title><title level="j" type="abbrev">Med Microbiol Immunol</title><idno type="ISSN">0300-8584</idno><idno type="eISSN">1432-1831</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2002-12-01">2002-12-01</date><biblScope unit="volume">191</biblScope><biblScope unit="issue">3-4</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="201">201</biblScope></imprint><idno type="ISSN">0300-8584</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-8584</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Influenza Pandemic Vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract.: During normal interpandemic influenza seasons, immune responses to vaccines are quite predictable and meet the licensing criteria of the European Union (EU) Committee for Proprietary Medicinal Products (CPMP). In a pandemic situation, large sections, if not all of the community will be immunologically naïve and therefore new immunisation strategies will be needed. In 1976 and 1977 H1N1 vaccines were prepared and tested clinically. To stimulate 'protective' antibody responses, two doses of vaccine were needed in people below the age of 24 years (no previous experience of H1N1 virus), whereas one conventional dose was adequate in older people. In 1997, the highly pathogenic avian influenza H5N1 virus caused widespread concern when it infected man, with lethal effects. Due to safety concerns it was necessary to adopt new strategies for vaccine development and one such strategy was to produce vaccine from an avirulent H5N3 virus, A/Duck/Singapore-Q/F119-2/97. Clinical trials of a subunit vaccine prepared from A/Duck/Sing/97 virus revealed that even two doses of twice the normal vaccine concentration (i.e. 30 µg haemagglutinin) were poorly immunogenic, whereas an H5N3 vaccine adjuvanted with microfluidised emulsion (MF) 59 stimulated antibody levels that complied with CPMP criteria after two half strength doses (i.e. 7.5 µg haemagglutinin).</div></front></TEI><affiliations><list><country><li>Italie</li><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Wood, J" sort="Wood, J" uniqKey="Wood J" first="J." last="Wood">J. Wood</name></noRegion><name sortKey="Major, D" sort="Major, D" uniqKey="Major D" first="D." last="Major">D. Major</name><name sortKey="Newman, R" sort="Newman, R" uniqKey="Newman R" first="R." last="Newman">R. Newman</name><name sortKey="Nicholson, K" sort="Nicholson, K" uniqKey="Nicholson K" first="K." last="Nicholson">K. Nicholson</name><name sortKey="Stephenson, I" sort="Stephenson, I" uniqKey="Stephenson I" first="I." last="Stephenson">I. Stephenson</name><name sortKey="Wood, J" sort="Wood, J" uniqKey="Wood J" first="J." last="Wood">J. Wood</name><name sortKey="Zambon, M" sort="Zambon, M" uniqKey="Zambon M" first="M." last="Zambon">M. Zambon</name></country><country name="Italie"><noRegion><name sortKey="Podda, A" sort="Podda, A" uniqKey="Podda A" first="A." last="Podda">A. Podda</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001777 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001777 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:531EA83777D63FF171A11EEEF568B5B739EF8C08
|texte= Experience with the clinical development of influenza vaccines for potential pandemics
}}
| This area was generated with Dilib version V0.6.33. |  |